Hosted on MSN1mon
A2 Biotherapeutics raises $80m to advance CAR-T therapies for solid tumours
EVEREST-1 (NCT05736731) evaluates A2B530, targeting carcinoembryonic antigen (CEA) for pancreatic, lung, and colorectal cancers. Both programmes utilise the BASECAMP-1 pre-screening study ...
Nature2mon
Blood test may provide early warning for returning colorectal cancer
The current guidelines for post-curative treatment monitoring of CRC rely on a serial blood biomarker known as CEA (carcinoembryonic antigen) and CT imaging. Despite CEA testing being standard of ...
News Medical1mon
Tracking cfDNA levels may help better evaluate surgery colorectal cancer effectiveness
The increases were even higher in individuals over 60, those with preexisting conditions such as diabetes or heart disease, and patients with elevated levels of carcinoembryonic antigen (CEA), a ...
Medical Xpress25d
Screening device detecting lung cancer biomarkers shows promise for early lung cancer detection
The study focused on developing highly sensitive sensors for two key lung cancer biomarkers: neuron-specific enolase (NSE) and carcinoembryonic antigen (CEA). The sensors were tested with buffer ...
Medscape8d
Differential Diagnosis of Intrahepatic Bile Duct Dilatation Without Demonstrable Mass On Ultrasonography or CT: Benign Versus Malignancy
such as bile cytology and bile carcinoembryonic antigen (CEA) levels, and dual phase CT or magnetic resonance (MR) sequences should be obtained before a confident diagnosis is made. [14] To ...
Business Wire1mon
A2 Biotherapeutics Closes $80 Million Series C Financing to Advance Clinical Development of Its Precision Cell Therapies Using Its Proprietary Tmod™ Technology Platform
A2 Bio is currently conducting two seamless phase 1/2 clinical studies: EVEREST-1 studying A2B530 for pancreatic, lung and colorectal cancers by targeting carcinoembryonic antigen (CEA); and ...